<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618186</url>
  </required_header>
  <id_info>
    <org_study_id>17-008710</org_study_id>
    <secondary_id>5P50AG016574-20</secondary_id>
    <nct_id>NCT03618186</nct_id>
  </id_info>
  <brief_title>Tau PET Imaging in African Americans</brief_title>
  <official_title>Tau PET Imaging in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to gather information and learn more about imaging tests in
      racially different people who are cognitively normal or have dementia.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tau positive scans</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of each of the three groups with tau positive scans</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively normal volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cogntive impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Person with cognitive impairment that meet Peterson Criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Demented</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient's that meet dementia criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Tau PET scan</intervention_name>
    <description>Patient will receive a dose of flutaucipir and be scanned appropriately</description>
    <arm_group_label>Demented</arm_group_label>
    <arm_group_label>Mild Cogntive impairment</arm_group_label>
    <arm_group_label>Normal control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female African Americans 30 years of age or older

          -  Subjects who have completed or are scheduled to undergo the neurological evaluation
             procedures described below.

        Exclusion Criteria:

          -  Subjects unable to lie down without moving for 20 minutes.

          -  Women who are pregnant or cannot stop breast feeding for 24 hours.

          -  Claustrophobic patients unable to tolerate the scans.

          -  Subjects with a prolonged QT interval (as demonstrated by ECG test) cannot participate
             in the Tau-PET scans.

          -  Standard safety exclusionary criteria for MRI such as metallic foreign bodies,
             pacemaker, etc, since the quantitative PET data analysis is based on anatomic criteria
             that are established uniquely for each subject by registration to his/her MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neill R Graff-Radford</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Neill R. Graff-Radford, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>African Americans</keyword>
  <keyword>neurological exam</keyword>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

